This research contributes to the expanding repertoire of model CSLC lines identified and characterized by MacroGenics and increases the number of important models from which MacroGenics can generate antibody-based drug candidates.
"Our Cancer Stem-like Cell Platform provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them.
Ongoing research at MacroGenics furthers our understanding of cancer stem cell biology and its significance in oncology treatment based on the role of these cells in tumor re-growth and metastasis." said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics.
In the publication, Isolation of Cancer Stem Like Cells from Human Adenosquamous Carcinoma of the Lung Supports a Monoclonal Origin from a Multipotential Tissue Stem Cell, investigators from MacroGenics describe CSLCs isolated from patients with ASC of the lung using defined serum-free culture conditions. ASC is a subtype of non-small cell lung cancer (NSCLC), a cancer characterized by tumors that contain cells with both squamous and adenocarcinoma (AC) histological phenotypes.
The isolated CSLCs display the properties of self-renewal, tumorigenicity, metastasis and the potential to undergo multi-lineage differentiation, all of which are associated with cancer stem cells. This research furthers the hypothesis that ASC tumors arise from a monoclonal origin derived from a common, as yet unidentified, precursor.